LGND Stock Analysis Today
Updated Nov 12, 2026 · trends, key levels, insider activity and news
Is LGND bullish or bearish today?
Daily trend: Uptrend (confirmed) — turns down below $250.37
SEPT signal: Institutional Drive · Bullish
Research grade: B+ · fair value $215.65 (+12.7%)
LGND trend by timeframe
| Daily | Uptrend (confirmed) |
|---|---|
| 4 hour | Bullish |
| 1 hour | Leaning Bearish |
| 15 min | Bearish |
| 5 min | Consolidating |
Trends are calculated from price structure and update during market hours.
LGND support and resistance levels
Resistance (above)
$317.644 touches
Support (below)
$302.376 touches
$281.7410 touches
$250.378 touches
Upside zones: $325.52 / $327.78 / $330.04
See all levels on the live chart →Insider and institutional activity
Insiders
Sell30-day buys / sells
0 / 4430-day net
-$2.3MHedge fund holders
337Latest LGND news and filings
- SEC FilingSECLigand Pharmaceuticals Inc filed an insider trading report (Form 4)
Form 4 reports shares bought or sold by company insiders such as officers, directors or large holders.
- AnalystBenzinga
Citigroup keeps Buy rating on Ligand Pharmaceuticals, lifts target to $402
Citigroup reiterated its Buy rating on Ligand Pharmaceuticals and raised its price target to $402. The change reflects the analyst's updated view on the stock.
- NewsFiscal.ai
Ligand Pharmaceuticals Insider Sells Company Stock
An executive at Ligand Pharmaceuticals sold shares of the company's stock. The filing discloses the transaction but provides no stated reason for the sale.
- DealFiscal.ai
Ligand Pharmaceuticals takes part in Pelthos Therapeutics PIPE financing
Ligand Pharmaceuticals is participating in a PIPE financing for Pelthos Therapeutics. A PIPE is a private placement of shares to selected investors.
- AnalystBenzinga
RBC Capital keeps Outperform on Ligand Pharmaceuticals, lifts target to $357
RBC Capital reiterated its Outperform rating on Ligand Pharmaceuticals and raised its price target to $357. The update reflects the analyst's revised expectations for the company.
- AnalystFiscal.ai
RBC Lifts Its Ligand Pharmaceuticals Target to $357 From $345
RBC now sees Ligand Pharmaceuticals worth $357 per share, up from $345. The firm revised its valuation for the drug developer.
Live LGND chart with trend icons on every timeframe, key levels, dark pool and options flow, news alerts, and Ask GOAX for a full analysis on demand.
Start free 7-day trialFrequently asked questions
Why did LGND stock move on Oct 29, 2026?
Oct 29, 2026: Ligand Pharmaceuticals reported third-quarter 2026 results, with adjusted earnings of $2.67 per share beating the $2.38 consensus and revenue of $78.700 million topping the $77.232 million projection. The company also raised its fiscal 2026 adjusted EPS guidance to $9.50-$9.75 from $9.00-$9.50, though it cut its sales forecast to $225 million-$250 million from $270 million-$310 million.
Is LGND bullish or bearish today?
LGND daily trend: Uptrend (confirmed) — turns down below $250.37. SEPT signal: Institutional Drive (Bullish). Updated Nov 12, 2026.
What is LGND's trend on each timeframe?
Daily: Uptrend (confirmed); 4 hour: Bullish; 1 hour: Leaning Bearish; 15 min: Bearish; 5 min: Consolidating.
What are LGND support and resistance levels?
Support: $302.37, $281.74, $250.37. Resistance: $317.64. Last price $316.83.
Are insiders buying or selling LGND?
Insider signal: Sell. Last 30 days: 0 buys, 44 sells, net -$2.3M. 337 hedge funds hold LGND.
What is the latest news on LGND?
Nov 6, 2026: Ligand Pharmaceuticals Inc filed an insider trading report (Form 4) · Nov 5, 2026: Citigroup keeps Buy rating on Ligand Pharmaceuticals, lifts target to $402 · Nov 4, 2026: Ligand Pharmaceuticals Insider Sells Company Stock